-
1 month ago | 
kanebridgenews.com | Don Nico Forbes
Squeezed out by highballs and quality Japanese malts, the country’s sake breweries are trying to innovate to win back market share.
-
1 month ago | 
wsj.com | Don Nico Forbes
March 17, 2025 11:00 pm ETOSAKA, Japan—The Japanese have been drinking sake since the eighth century. Back then, it was believed the rice-based liquor warded off ghosts. Today, it has a stronger spirit to contend with: whisky. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
-
2 months ago | 
morningstar.com | Don Nico Forbes
By Don Nico Forbes Workday outlined a restructuring plan which will result in a reduction of about 1,750 jobs, or 8.5% of its current workforce. The human-resources software company said Wednesday that the plan is intended to prioritize investments and growth, and will also involve exiting certain owned office spaces.
-
2 months ago | 
tradingview.com | Don Nico Forbes
Workday to Cut About 1,750 JobsWDAYWorkday outlined a restructuring plan which will result in a reduction of about 1,750 jobs, or 8.5% of its current workforce. The human-resources software company said Wednesday that the plan is intended to prioritize investments and growth, and will also involve exiting certain owned office spaces.
-
2 months ago | 
tradingview.com | Don Nico Forbes
Halliburton Wins Offshore Drilling Contract With PetrobrasPETR3HALHalliburton said it won a contract with Petrobras to provide drilling services at several offshore fields in Brazil. The oil service company said the contract includes drilling services for development and exploration wells over a three-year period. The contract is expected to begin in 2025, and represents Halliburton's largest service contract with Petrobras, it said.
-
2 months ago | 
tradingview.com | Don Nico Forbes
Altria Profit Rose in 4Q, Revenue FlatMOAltria profit rose in the fourth quarter, with revenue flat as lower smokeable-product sales were offset by higher oral-tobacco revenue. The maker of Marlboro cigarettes reported on Thursday a profit of $3.04 billion, or $1.79 a share, up from $2.06 billion, or $1.16 a share, in the year-prior period. On an adjusted basis, earnings per share were $1.29, against analyst views of $1.28, according to FactSet. Revenue was flat at $5.97 billion.
-
2 months ago | 
tradingview.com | Don Nico Forbes
Thermo Fisher Scientific Profit, Revenue Rose in 4QTMOThermo Fisher Scientific posted higher profit and revenue in the fourth quarter, and expressed confidence for the year ahead. The Waltham, Mass., maker of microscopes and other life-sciences and laboratory equipment said profit rose to $1.83 billion, or $4.78 a share, from $1.63 billion, or $4.20 a share, a year earlier. Adjusted third-quarter earnings came in at $6.10 a share, beating analyst views of $5.94 a share, according to FactSet.
-
2 months ago | 
tradingview.com | Don Nico Forbes
Honda to Recall More Than 290,000 Vehicles Due to Software Issue7267Honda is recalling 294,612 vehicles in the U.S. due to a software issue which can cause the engine of certain models to stall, according to the National Highway Traffic Safety Administration. The U.S. auto regulator said the issue--which affects certain 2022-25 Acura MDX Type-S, 2023-25 Honda Pilot, and 2021-25 Acura TLX Type-S vehicles--can cause a loss of power, increasing the risk of a crash or injury.
-
Jan 21, 2025 | 
tradingview.com | Don Nico Forbes
Evolus Shares Rise on Jump in RevenueEOLSShares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance. Shares were up 16% in premarket trading at $12.20. The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million.
-
Jan 21, 2025 | 
tradingview.com | Don Nico Forbes
Atara's New Drug Applications Placed on Hold by FDAATRAAtara Biotherapeutics said the U.S. Food and Drug Administration placed a clinical hold on its active investigational new drug applications. The biotechnology company said the FDA put a hold on its Ebvallo and ATA3219 programs due to compliance issues at a third-party manufacturing facility. Ebvallo is a treatment candidate for Epstein-Barr virus positive post-transplant lymphoproliferative disease, or EBV+PTLD.
